MC
NVO

Mathes Company’s Novo Nordisk NVO Stock Holding History

Mathes Company’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,191
Closed -$499K – 127
2024
Q3 		$499K Sell
4,191
-154
-4% -$20.5K 0.18% 89
2024
Q2 		$620K Sell
4,345
-265
-6% -$35.1K 0.23% 80
2024
Q1 		$592K Sell
4,610
-100
-2% -$11.9K 0.22% 84
2023
Q4 		$487K Sell
4,710
-255
-5% -$25.2K 0.2% 90
2023
Q3 		$452K Buy
4,965
+1,145
+30% +$101K 0.21% 89
2023
Q2 		$309K Buy
+3,820
New +$312K 0.14% 105
2022
Q4 		$258K Buy
+3,820
New +$224K 0.13% 112
2022
Q3 		– Sell
-3,800
Closed -$212K – 130
2022
Q2 		$212K Sell
3,800
-60
-2% -$3.33K 0.1% 121
2022
Q1 		$214K Buy
3,860
+3,428
+794% +$176K 0.08% 127
2021
Q4 		$1.93M Buy
+432
New +$23.4K 0.66% 55

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Mathes Company's NVO Position: Q4 2024 in Review

Mathes Company sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 4,191 shares — an estimated $499K sold.

Mathes Company first reported a position in NVO in Q4 2021 and held it in 10 quarters. The position peaked at $1.93M in Q4 2021. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Mathes Company reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Mathes Company sold 4,191 Novo Nordisk shares in Q4 2024, an estimated $499K.
  • Mathes Company first reported a position in Novo Nordisk in Q4 2021 and held it in 10 quarters.
  • Mathes Company's Novo Nordisk position peaked at $1.93M in Q4 2021.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Mathes Company's 13F filing for Q4 2024, filed 31 Jan 2025.